Recro Pharma Total Revenue

Recro Pharma (REPH) currently reports a total revenue of $95M as of December 2023. That compares with $90M in the prior-year period — up 4.9% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Recro Pharma's total revenue history and peer comparisons.

Recro Pharma's total revenue increased from $90M to $95M — a 4.9% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recro Pharma's total revenue of $95M is lower than the Healthcare sector average of $110B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Recro Pharma reported $95M in total revenue as of December 2023. That compares with $90M in the prior-year period — up 4.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $95M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Recro Pharma, and consider following REPH for alerts when major investors trade the stock.